Premium
Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment
Author(s) -
DE OLIVEIRA Juliana Pedroso,
LEVY Annabelle,
MOREL Patrice,
GUIBAL Fabien
Publication year - 2008
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2008.00525.x
Subject(s) - infliximab , medicine , psoriasis , adverse effect , anti nuclear antibody , psoriasis area and severity index , gastroenterology , surgery , dermatology , disease , immunology , antibody , autoantibody
Infliximab treatment has been shown to be effective for moderate‐to‐severe psoriasis in several large clinical trials. Nonetheless, experience with this new treatment is still needed to evaluate its efficacy and tolerance in everyday practice. In this follow‐up study, we report our experience with infliximab for recalcitrant psoriasis. Nineteen patients with recalcitrant psoriasis were treated between July 2004 and December 2006 with 5 mg/kg infliximab i.v. at weeks 0, 2 and 6 followed by maintenance every 8 weeks. In three patients resistant to treatment, methotrexate was added at a 15–25 mg dose weekly after the sixth week of infliximab therapy. Pretreatment evaluations included chest X‐ray, tuberculin test (5 units), full blood count, kidney and liver function tests, antinuclear antibodies and patient weight. Response to treatment, using the Psoriasis Area and Severity Index (PASI) score, and adverse effects were prospectively assessed at weeks 0, 6 and 22. At week 6, after only two infusions, 78.9% (15/19) of patients showed at least 75% improvement in baseline PASI (PASI 75). At week 22, 73.6% (14/19) patients had reached PASI 75. Three patients had a relapse. Four developed adverse effects that required suspension of infliximab therapy. No tuberculosis or lymphoproliferative disease was observed. Four patients (21%) showed apparition of positive antinuclear antibody during the course of treatment and 57.8% (11/19) of patients showed an increase in weight at week 22. Our experience shows that infliximab is a very rapidly effective treatment of severe, treatment‐resistant psoriasis as soon as the sixth week of treatment.